Characteristics of 797 patients subjected to targeted-capture sequencing
| Characteristic . | No. of cases (%) . | Median (range) . |
|---|---|---|
| Patient sex (n = 797) | ||
| Male | 502 (63.0) | |
| Female | 295 (37.0) | |
| Age at diagnosis (n = 796), y | 51 (12-65) | |
| Age at transplantation (n = 797), y | 53 (16-66) | |
| Time from diagnosis to transplantation (n = 793), mo | 9.4 (0.2-363) | |
| Prior diagnosis (n = 797) | ||
| Lower-risk MDS | 276 (34.6) | |
| Higher-risk MDS | 307 (38.5) | |
| RAEB-t | 58 (7.3) | |
| MDS/MPN | 55 (6.9) | |
| Myelodysplasia not otherwise specified | 101 (12.7) | |
| IPSS (n = 532) | ||
| Low | 42 (7.9) | |
| Int-1 | 237 (44.5) | |
| Int-2 | 178 (33.5) | |
| High | 75 (14.1) | |
| Karyotype*(n = 770) | ||
| Low risk | 342 (44.4) | |
| Intermediate risk | 188 (24.4) | |
| High risk | 240 (31.2) | |
| Complex | 137 (17.8) | |
| Diagnosis at transplantation (n = 760) | ||
| Lower-risk MDS | 242 (30.4) | |
| Higher-risk MDS | 283 (35.5) | |
| sAML† | 189 (23.7) | |
| MDS/MPN | 46 (5.8) | |
| Disease status (n = 771) | ||
| No prior history of treatment | 314 (39.4) | |
| Complete remission | 104 (13.0) | |
| Partial remission | 122 (15.3) | |
| Refractory/relapsed disease | 231 (29.0) | |
| Year of transplantation (n = 794) | 2010 (1998-2014) | |
| Graft source (n = 797) | ||
| Bone marrow | 794 (99.6) | |
| Peripheral blood | 3 (0.4) | |
| Donor sex (n = 795) | ||
| Male | 555 (69.8) | |
| Female | 240 (30.2) | |
| HLA disparity (no. of serological mismatch) (n = 796) | ||
| 0/6 | 640 (80.4) | |
| 1/6 | 151 (19.0) | |
| 2/6 | 5 (0.6) | |
| Patient-donor sex disparity (n = 795) | ||
| No mismatch | 463 (58.2) | |
| Female-male | 193 (24.3) | |
| Male-female | 139 (17.5) | |
| GVHD prophylaxis (n = 797) | ||
| Tacrolimus and methotrexate | 606 (76.0) | |
| Cyclosporine and methotrexate | 129 (16.2) | |
| Others | 62 (7.8) | |
| Performance status at transplantation (n = 729) | ||
| 0-2 | 676 (92.7) | |
| ≥3 | 53 (7.3) | |
| History of RBC transfusion (n = 642) | ||
| + | 566 (88.2) | |
| − | 76 (11.8) | |
| History of platelet transfusion (n = 637) | ||
| + | 475 (74.6) | |
| − | 162 (25.4) | |
| Intensity of conditioning regimen (n = 784) | ||
| Myeloablative | 511 (65.2) | |
| Reduced-intensity | 273 (34.8) | |
| Conditioning regimen menu (n = 797) | ||
| TBI-based | 220 (27.6) | |
| HCT-CI score (n = 630) | ||
| 0 | 360 (57.1) | |
| 1-2 | 159 (25.2) | |
| ≥3 | 111 (17.6) |
| Characteristic . | No. of cases (%) . | Median (range) . |
|---|---|---|
| Patient sex (n = 797) | ||
| Male | 502 (63.0) | |
| Female | 295 (37.0) | |
| Age at diagnosis (n = 796), y | 51 (12-65) | |
| Age at transplantation (n = 797), y | 53 (16-66) | |
| Time from diagnosis to transplantation (n = 793), mo | 9.4 (0.2-363) | |
| Prior diagnosis (n = 797) | ||
| Lower-risk MDS | 276 (34.6) | |
| Higher-risk MDS | 307 (38.5) | |
| RAEB-t | 58 (7.3) | |
| MDS/MPN | 55 (6.9) | |
| Myelodysplasia not otherwise specified | 101 (12.7) | |
| IPSS (n = 532) | ||
| Low | 42 (7.9) | |
| Int-1 | 237 (44.5) | |
| Int-2 | 178 (33.5) | |
| High | 75 (14.1) | |
| Karyotype*(n = 770) | ||
| Low risk | 342 (44.4) | |
| Intermediate risk | 188 (24.4) | |
| High risk | 240 (31.2) | |
| Complex | 137 (17.8) | |
| Diagnosis at transplantation (n = 760) | ||
| Lower-risk MDS | 242 (30.4) | |
| Higher-risk MDS | 283 (35.5) | |
| sAML† | 189 (23.7) | |
| MDS/MPN | 46 (5.8) | |
| Disease status (n = 771) | ||
| No prior history of treatment | 314 (39.4) | |
| Complete remission | 104 (13.0) | |
| Partial remission | 122 (15.3) | |
| Refractory/relapsed disease | 231 (29.0) | |
| Year of transplantation (n = 794) | 2010 (1998-2014) | |
| Graft source (n = 797) | ||
| Bone marrow | 794 (99.6) | |
| Peripheral blood | 3 (0.4) | |
| Donor sex (n = 795) | ||
| Male | 555 (69.8) | |
| Female | 240 (30.2) | |
| HLA disparity (no. of serological mismatch) (n = 796) | ||
| 0/6 | 640 (80.4) | |
| 1/6 | 151 (19.0) | |
| 2/6 | 5 (0.6) | |
| Patient-donor sex disparity (n = 795) | ||
| No mismatch | 463 (58.2) | |
| Female-male | 193 (24.3) | |
| Male-female | 139 (17.5) | |
| GVHD prophylaxis (n = 797) | ||
| Tacrolimus and methotrexate | 606 (76.0) | |
| Cyclosporine and methotrexate | 129 (16.2) | |
| Others | 62 (7.8) | |
| Performance status at transplantation (n = 729) | ||
| 0-2 | 676 (92.7) | |
| ≥3 | 53 (7.3) | |
| History of RBC transfusion (n = 642) | ||
| + | 566 (88.2) | |
| − | 76 (11.8) | |
| History of platelet transfusion (n = 637) | ||
| + | 475 (74.6) | |
| − | 162 (25.4) | |
| Intensity of conditioning regimen (n = 784) | ||
| Myeloablative | 511 (65.2) | |
| Reduced-intensity | 273 (34.8) | |
| Conditioning regimen menu (n = 797) | ||
| TBI-based | 220 (27.6) | |
| HCT-CI score (n = 630) | ||
| 0 | 360 (57.1) | |
| 1-2 | 159 (25.2) | |
| ≥3 | 111 (17.6) |
In multivariate modeling, all of the missing data were imputed for each variable in all of the noninformative cases.
GVHD, graft-versus-host disease.
Karyotyping score is according to the criteria applied in IPSS.
sAML included patients with AML evolving from myelodysplasia, and those diagnosed with RAEB-t according to the French-American-British classification.